Dr. Lal PathLabs is coming out with a 100% book building; initial public offering (IPO) of 11,600,000 shares of Rs 10 each in a price band Rs 540-550 per equity share to raise Rs 638 crore. Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
The issue will open for subscription on December 8, 2015 and will close on December 10, 2015. The shares will be listed on BSE as well as NSE. The face value of the share is Rs 10 and is priced 54 times of its face value on the lower side and 55 times on the higher side.
Book running lead managers to the issue are Kotak Mahindra Capital Company and Citigroup Global Markets India, while compliance officer for the issue is Rajat Kalra.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7248.75 |
Max Healthcare Inst | 1166.60 |
Narayana Hrudayalay | 1286.30 |
Aster DM Healthcare | 486.85 |
Global Health | 1098.95 |
View more.. |